publication date: Apr. 26, 2019

Texas House of Representatives approves two CPRIT measures

By Claire Dietz

The Texas House of Representatives approved two measures that would give the Cancer Prevention and Research Institute of Texas an additional $3 billion to continue operations, and allow the institute to continue funding grants beyond fiscal year 2023.

The measures approved earlier this month are:

House Joint Resolution 12, which authorizes $3 billion in new bond funding, known as General Obligation Bonds, and

House Bill 39, which remove a restriction against new grant awards beyond CPRIT’s initial sunset date in 2023.

  

“It’s very gratifying to hear from the state leadership, both the recognition of what CPRIT has accomplished and, in addition, the understanding of what’s ahead of us in terms of continued opportunity to make an impact in cancer in Texas,” James Willson, CPRIT chief scientific officer, said to The Cancer Letter (The Cancer Letter, March 22).

“And that leads us to be quite optimistic about the future continuation of this investment.”

“We are encouraged by the House’s overwhelmingly positive vote in support of the continuation of CPRIT,” said Peter WT Pisters, president of The University of Texas MD Anderson Cancer Center. “It’s clear that the tremendous impact of CPRIT has been recognized, and we remain committed to this vital and unique resource that establishes Texas as a world leader in cancer research, prevention and commercialization of discovery.”

“While This is very good news these are the first step as the reauthorization bill is now being considered by the … Continue reading Texas House of Representatives approves two CPRIT measures

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.